Blood-based genomics, transcriptomics, and immune responses in early-onset ad
Active Grant Awarded
- Award ID
- R01AG096763
- Recipient
-
The Regents Of The University Of California. San Francisco UEI KMH5K9V7S518
- Awarding agency
-
National Institute on Aging
National Institutes of Health, Department of Health and Human Services
- Obligated
- $708,793
Award facts
- Assistance listing
- 93.866 Aging Research
- Completion date 4% complete
- Place of performance
- California, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services' National Institutes of Health, through its National Institute on Aging, awarded The Regents of the University of California, San Francisco, acting through its Controller's Office, $708,793 on September 9, 2026, under Assistance Listing 93.866, Aging Research, via Grant R01AG096763. The recipient will generate and analyze genomic and immune data on early-onset Alzheimer's disease (EOAD), defined by symptom onset at or before age 65. Whole genome sequencing data from approximately 1,900 participants of the UCSF Memory and Aging Center will be analyzed alongside WGS data from the US-Latin American project REDLAT (approximately 2,800 participants) and the Alzheimer's Disease Sequencing Project (approximately 18,000 participants) to identify rare variation underlying EOAD risk across a broader range of genetic ancestries. The study will also perform single-cell RNA sequencing of peripheral blood mononuclear cells, generating the largest public single-cell resource of EOAD immune data (720,000+ PBMC transcriptomes). It will assess sex differences in EOAD immune cell repertoires and use T cell receptor sequencing to determine whether interferon-responsive CD4 T cells are clonally expanded in EOAD.
The period of performance runs from the September 9, 2026 award date to an ultimate completion date of May 31, 2031. Place of performance is California, USA. The Aging Research program supports biomedical, social, and behavioral research on the aging process and its diseases, with the National Institute on Aging emphasizing prevention and treatment of Alzheimer's disease and related dementias.
Description
- Abstract
- Early-onset alzheimer's disease (EOAD), characterized by the same neuropathology as late-onset alzheimer's disease (LOAD), is defined by symptom onset at or before age 65. EOAD patients frequently experience atypical clinical symptoms and an aggressive clinical course, resulting in delayed diagnosis and exclusion from clinical trials. Critically, even though EOAD has a stronger heritable component than LOAD, the majority of EOAD-specific genetic risk remains undefined. To address this major knowledge GAP, this project will uncover novel contributions to EOAD risk through a multimodal sequencing approach. First, the proposed study will probe rare variation underlying EOAD risk by leveraging newly generated whole genome sequencing (WGS) data from ~1,900 participants from the ucsf memory and aging center. This analysis will be augmented by incorporating WGS data from the US-latin american project, redlat (~2,800 participants), and the alzheimer's disease sequencing project (~18,000 participants), with both cohorts representing a broader spectrum of genetic ancestries than any previous genomic studies of EOAD. Intriguingly, single-cell RNA sequencing analysis of peripheral blood mononuclear cells (PBMCS) indicates that EOAD patients possess a unique expansion of highly interferon (IFN)- responsive CD4 T cells; this rare T cell subset is also expanded in autoimmune diseases and viral encephalitis. Given this finding was driven largely by females, the proposed study will directly assess SEX differences in EOAD immune cell repertoires, generating the largest public single-cell resource of EOAD immune data (720,000+ pbmc transcriptomes). Analysis of T cell receptor sequencing data in this dataset will address the crucial question of whether IFN-responsive CD4 T cells are clonally expanded in EOAD, as they are in autoimmune disease. Finally, leveraging state-of-the-art techniques in single-cell proteomics and "6-base" DNA methylation sequencing, this study will carry out the first isolation and functional characterization of IFN-responsive CD4 T cells. Together, this study will profoundly impact the field's understanding of EOAD risk through the following specific aims: (1) identify novel genetic risk variants in EOAD, (2) determine whether the highly IFN-responsive CD4 T cells increased in EOAD are driven by female SEX and clonally expanded, and (3) isolate and characterize circulating IFN-responsive CD4 T cells from EOAD cases and controls. In pursuing these aims, this study will fill a major GAP in knowledge regarding EOAD-specific genetic risk and the unique pathobiology that results in early disease onset. This study will pursue innovative work in gene discovery and immune transcriptomics in EOAD, where there is unmet need for accessible, predictive biomarkers to facilitate faster diagnosis. Finally, this study will generate unique, large-scale, multi-omic datasets for the community, and has the potential to identify new targets for disease intervention that are amenable to immunotherapy.
Quick answers
Who received award R01AG096763?
R01AG096763 was awarded to The Regents Of The University Of California. San Francisco by National Institute on Aging (National Institutes of Health) on September 9, 2026.
How much is award R01AG096763 worth?
$708,793 has been obligated on R01AG096763.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award